{
    "clinical_study": {
        "@rank": "19898", 
        "acronym": "CICLODECH", 
        "arm_group": [
            {
                "arm_group_label": "Arm A", 
                "arm_group_type": "Experimental", 
                "description": "Graft versus host disease prophylaxis will be done with cyclophosphamide 50 mg/kg on day +3 and day +4"
            }, 
            {
                "arm_group_label": "Arm B", 
                "arm_group_type": "Active Comparator", 
                "description": "In this arm, patients will receive a combination of methotrexate and a calcineurin inhibitor as graft versus host disease prophylaxis"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether cyclophosphamide post bone marrow\n      transplant increases the rate of patients alive, in remission and without immunosuppression,\n      one year after transplant, when compared with the combination of methotrexate and\n      calcineurin inhibitor"
        }, 
        "brief_title": "Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Myelogenous Leukemia", 
            "Acute Lymphoid Leukemia", 
            "Myeloproliferative Disease", 
            "Myelodysplastic Syndrome", 
            "Chronic Myeloid Leukemia", 
            "Chronic Myelomonocytic Leukemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Graft vs Host Disease", 
                "Leukemia", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", 
                "Leukemia, Myelomonocytic, Chronic", 
                "Myelodysplastic Syndromes", 
                "Preleukemia", 
                "Leukemia, Myelomonocytic, Acute", 
                "Myeloproliferative Disorders"
            ]
        }, 
        "detailed_description": {
            "textblock": "We propose a study in which 150 patients will receive graft versus host disease prophylaxis\n      with cyclophosphamide 50 mg/kg on day +3 and day +4 after bone marrow transplantation, and\n      150 patients will receive the usual combination of methotrexate and calcineurin inhibitor.\n      The study was designed to last for 4 years. The primary endpoint is the rate of patients\n      alive, in remission and without immunosuppression, one year after transplant. The assignment\n      for each arm of the study will be done through simple randomization."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Man or woman 18 to 60 years of age.\n\n          -  The patient should have a HLA matched donor\n\n          -  The patient must need a bone marrow transplant for a malignant disease (Acute\n             leukemia, myelodysplastic syndrome, myeloproliferative disease or\n             myelodysplastic/myeloproliferative disease)\n\n          -  Patients want to participate in the study, and able to give informed consent.\n\n        Exclusion Criteria:\n\n          -  Previous auto o allogeneic hematopoietic stem cell transplant\n\n          -  Performance Status >2 (ECOG).\n\n          -  Pregnancy\n\n          -  HIV positive\n\n          -  Active Infection\n\n          -  Cardiac disease with ejection fraction < 45%\n\n          -  Lung disease with FEV1, FVC ou DLCO <50% of predicted values.\n\n          -  Renal Insufficiency with creatinine clearance < 60 ml/minute.\n\n          -  Liver disease with bilirubin levels  >  twice the reference value or ALT or AST >\n             three times the normal reference."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 11, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01749111", 
            "org_study_id": "GEDECH-2012"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A", 
                "description": "Cyclophosphamide 50 mg/kg on day+3 and day+4 after bone marrow transplantation", 
                "intervention_name": "ARM A Cyclophosphamide", 
                "intervention_type": "Drug", 
                "other_name": "Cyclophosphamide"
            }, 
            {
                "arm_group_label": "Arm B", 
                "description": "Graft versus host disease prophylaxis will be done with the combination of a calcineurin inhibitor (either tacrolimus or cyclosporine) and methotrexate", 
                "intervention_name": "ARM B Calcineurin inhibitor and methotrexate", 
                "intervention_type": "Drug", 
                "other_name": "Calcineurin inhibitor and methotrexate"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Methotrexate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "bone marrow transplantation", 
            "graft versus host disease", 
            "Acute myelogenous leukemia", 
            "Acute lymphoid leukemia", 
            "Myeloproliferative disease", 
            "Myelodysplastic syndrome", 
            "Chronic myeloid leukemia", 
            "chronic myelomonocytic leukemia"
        ], 
        "lastchanged_date": "December 12, 2012", 
        "location": {
            "contact": {
                "email": "sandra.nakashima@einstein.br", 
                "last_name": "Sandra S Nakashima, Nurse", 
                "phone": "0055 11 2151 1128"
            }, 
            "contact_backup": {
                "email": "isabel.bello@einstein.br", 
                "last_name": "Isabel C Bello, Nurse", 
                "phone": "0055 11 2151 1128"
            }, 
            "facility": {
                "address": {
                    "city": "S\u00e3o Paulo", 
                    "country": "Brazil", 
                    "zip": "05652-000"
                }, 
                "name": "Instituto Israelita de Ensino e Pesquisa Albert Einstein 's (IIEP)"
            }, 
            "investigator": {
                "last_name": "Paulo V Campregher, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Study to Compare Post Bone Marrow Transplant Cyclophosphamide With the Combination of Methotrexate Plus Calcineurin Inhibitor for Graft Versus Host Disease Prophylaxis", 
        "other_outcome": {
            "description": "Cumulative incidence of disease relapse, one year after bone marrow transplantation", 
            "measure": "Cumulative incidence of disease relapse, one year after bone marrow transplantation", 
            "safety_issue": "No", 
            "time_frame": "one year"
        }, 
        "overall_contact": {
            "email": "sandra.nakashima@einstein.br", 
            "last_name": "Sandra S Nakashima, Nurse", 
            "phone": "0055 11 2151 1128"
        }, 
        "overall_contact_backup": {
            "email": "isabel.bello@einstein.br", 
            "last_name": "Isabel C Bello, Nurse", 
            "phone": "0055 11 2151 1128"
        }, 
        "overall_official": {
            "affiliation": "Hospital Israelita Albert Einstein", 
            "last_name": "Paulo V Campregher, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Brazil: Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The rate of patients alive, in remission and without immunosuppression, one year after bone marrow transplantation.", 
            "measure": "The rate of patients alive, in remission and without immunosuppression, one year after bone marrow transplantation.", 
            "safety_issue": "No", 
            "time_frame": "one year"
        }, 
        "reference": {
            "PMID": "20124511", 
            "citation": "Luznik L, Bola\u00f1os-Meade J, Zahurak M, Chen AR, Smith BD, Brodsky R, Huff CA, Borrello I, Matsui W, Powell JD, Kasamon Y, Goodman SN, Hess A, Levitsky HI, Ambinder RF, Jones RJ, Fuchs EJ. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010 Apr 22;115(16):3224-30. doi: 10.1182/blood-2009-11-251595. Epub 2010 Feb 2."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01749111"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hospital Israelita Albert Einstein", 
            "investigator_full_name": "Paulo Vidal Campregher", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Cumulative incidence of chronic graft versus host disease, one year after bone marrow transplantation", 
            "measure": "Cumulative incidence of chronic graft versus host disease, one year after bone marrow transplantation", 
            "safety_issue": "No", 
            "time_frame": "one year"
        }, 
        "source": "Hospital Israelita Albert Einstein", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hospital Israelita Albert Einstein", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}